| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acute tolerance of Moderna mRNA-1273 vaccine against COVID-19 in patients with cancer treated with radiotherapy
|
Scoccianti, Silvia
|
|
|
22 |
9 |
p. 1212-1214
|
artikel
|
| 2 |
A decade of strengthening breast oncology in Ethiopia
|
Taylor, Lesley
|
|
|
22 |
9 |
p. 1219-1220
|
artikel
|
| 3 |
An important step towards smarter screening for prostate cancer
|
Moore, Caroline M
|
|
|
22 |
9 |
p. 1201-1202
|
artikel
|
| 4 |
Antiangiogenic agents combined with systemic chemotherapy in refractory osteosarcoma
|
Rutkowski, Piotr
|
|
|
22 |
9 |
p. 1206-1207
|
artikel
|
| 5 |
Asian minorities in Asian countries: intersecting disparities affecting minoritised groups
|
Dee, Edward Christopher
|
|
|
22 |
9 |
p. e381
|
artikel
|
| 6 |
Cancer care in Afghanistan after the Taliban takes over
|
Das, Manjulika
|
|
|
22 |
9 |
p. e390
|
artikel
|
| 7 |
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
|
Monk, Bradley J
|
|
|
22 |
9 |
p. 1275-1289
|
artikel
|
| 8 |
Clarifying allegations regarding CoEHAR conflicts of interest
|
Li Volti, Giovanni
|
|
|
22 |
9 |
p. e378
|
artikel
|
| 9 |
Correction to Lancet Oncol 2018; 19: 337–46
|
|
|
|
22 |
9 |
p. e389
|
artikel
|
| 10 |
Correction to Lancet Oncol 2021; 22: 1322–32
|
|
|
|
22 |
9 |
p. e389
|
artikel
|
| 11 |
Effect of removing race from glomerular filtration rate-estimating equations on anticancer drug dosing and eligibility: a retrospective analysis of National Cancer Institute phase 1 clinical trial participants
|
Casal, Morgan A
|
|
|
22 |
9 |
p. 1333-1340
|
artikel
|
| 12 |
eGFR and chemotherapy: will removing race create disparities?
|
Levey, Andrew S
|
|
|
22 |
9 |
p. 1208-1209
|
artikel
|
| 13 |
Genomic-adjusted radiation dose to personalise radiotherapy
|
Kaidar-Person, Orit
|
|
|
22 |
9 |
p. 1200-1201
|
artikel
|
| 14 |
Global cancer control: choosing the road less travelled
|
Mutebi, Miriam
|
|
|
22 |
9 |
p. 1209-1211
|
artikel
|
| 15 |
Increase in health-care cyberattacks affecting patients with cancer
|
Gourd, Elizabeth
|
|
|
22 |
9 |
p. 1215
|
artikel
|
| 16 |
Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study
|
Gaspar, Nathalie
|
|
|
22 |
9 |
p. 1312-1321
|
artikel
|
| 17 |
Non-AIDS-defining cancers in people living with HIV
|
Abbar, Baptiste
|
|
|
22 |
9 |
p. e382
|
artikel
|
| 18 |
Pan-cancer prediction of radiotherapy benefit using genomic-adjusted radiation dose (GARD): a cohort-based pooled analysis
|
Scott, Jacob G
|
|
|
22 |
9 |
p. 1221-1229
|
artikel
|
| 19 |
Partnership to tackle HCV in low-income and middle-income countries
|
Das, Manjulika
|
|
|
22 |
9 |
p. 1218
|
artikel
|
| 20 |
Paving a pathway for drug development in HER2-positive biliary tract cancer
|
Chen, Christopher T
|
|
|
22 |
9 |
p. 1204-1206
|
artikel
|
| 21 |
Pembrolizumab monotherapy for high-risk, non-muscle-invasive bladder cancer
|
Rentsch, Cyrill A
|
|
|
22 |
9 |
p. e379
|
artikel
|
| 22 |
Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer – Authors' reply
|
Balar, Arjun V
|
|
|
22 |
9 |
p. e380
|
artikel
|
| 23 |
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
|
Javle, Milind
|
|
|
22 |
9 |
p. 1290-1300
|
artikel
|
| 24 |
Pneumocephalus as a complication of basal cell carcinoma
|
Miletic, Bojan
|
|
|
22 |
9 |
p. e419
|
artikel
|
| 25 |
Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial
|
Nordström, Tobias
|
|
|
22 |
9 |
p. 1240-1249
|
artikel
|
| 26 |
Provision of mental health care for patients with cancer
|
The Lancet Oncology,
|
|
|
22 |
9 |
p. 1199
|
artikel
|
| 27 |
Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial
|
Yang, Wenyu
|
|
|
22 |
9 |
p. 1322-1332
|
artikel
|
| 28 |
Radiotherapy resources in Africa: an International Atomic Energy Agency update and analysis of projected needs
|
Elmore, Shekinah N C
|
|
|
22 |
9 |
p. e391-e399
|
artikel
|
| 29 |
Shortage of cancer drugs in Mexico
|
Das, Manjulika
|
|
|
22 |
9 |
p. 1216
|
artikel
|
| 30 |
Sintilimab plus IBI305 for hepatocellular carcinoma
|
Cheng, Luo
|
|
|
22 |
9 |
p. e387
|
artikel
|
| 31 |
Sintilimab plus IBI305 for hepatocellular carcinoma
|
Bomze, David
|
|
|
22 |
9 |
p. e386
|
artikel
|
| 32 |
Sintilimab plus IBI305 for hepatocellular carcinoma – Author's reply
|
Fan, Jia
|
|
|
22 |
9 |
p. e388
|
artikel
|
| 33 |
Stereotactic body radiotherapy for painful spinal metastases
|
Cellini, Francesco
|
|
|
22 |
9 |
p. e384
|
artikel
|
| 34 |
Stereotactic body radiotherapy for painful spinal metastases – Authors' reply
|
Sahgal, Arjun
|
|
|
22 |
9 |
p. e385
|
artikel
|
| 35 |
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials
|
Fallah, Jaleh
|
|
|
22 |
9 |
p. 1230-1239
|
artikel
|
| 36 |
Talazoparib: a new biomarker-directed therapy in advanced prostate cancer
|
Conteduca, Vincenza
|
|
|
22 |
9 |
p. 1203-1204
|
artikel
|
| 37 |
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial
|
de Bono, Johann S
|
|
|
22 |
9 |
p. 1250-1264
|
artikel
|
| 38 |
The impact of scaling up access to treatment and imaging modalities on global disparities in breast cancer survival: a simulation-based analysis
|
Ward, Zachary J
|
|
|
22 |
9 |
p. 1301-1311
|
artikel
|
| 39 |
The UK's contribution to cancer control in low-income and middle-income countries
|
Stanway, Susannah
|
|
|
22 |
9 |
p. e410-e418
|
artikel
|
| 40 |
Towards evidence-based personalised precision medicine for Lynch syndrome
|
Møller, Pål
|
|
|
22 |
9 |
p. e383
|
artikel
|
| 41 |
Transforming Canada's role in global cancer control
|
Rodin, Danielle
|
|
|
22 |
9 |
p. e400-e409
|
artikel
|
| 42 |
Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
|
Zhou, Xiaoxiang
|
|
|
22 |
9 |
p. 1265-1274
|
artikel
|
| 43 |
WHO releases latest report on the global tobacco epidemic
|
Burki, Talha Khan
|
|
|
22 |
9 |
p. 1217
|
artikel
|
Tijdschrift beschrijving